Oscar Juan-Vidal

18PUBLICATIONS
136CO-AUTHORS
Predictive and prognostic markersTransgender studiesMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cellular nervous system
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jun 01, 2025
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab.

Zofia Piotrowska, Antonio Passaro, Danny Nguyen

|Apr 18, 2025
Oncological needs in transgender patients.

Francisco Ayala de la Peña, David Martínez-Ramos, Oscar Juan-Vidal

|Nov 05, 2024
A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations.

Guillermo Suay, Paloma Martín-Martorell, Francisco Aparisi

|Sep 09, 2024
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

Myung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares

|Jul 17, 2024
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study.

Niels Reinmuth, Oscar Juan-Vidal, Dariusz Kowalski

|Jun 06, 2024
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.

Luis G Paz-Ares, Oscar Juan-Vidal, Giannis S Mountzios

Pageof 3

Frequent Collaborators

4 joint publications

Sarai Palanca

3 joint publications

Javier Simarro

3 joint publications

Luis Paz-Ares

3 joint publications

Enriqueta Felip